reSee.it Podcast Summary
Peter Attia and Dom D’Agostino explore the science, promise, and caveats of ketosis as a therapeutic and performance strategy. They trace Dom’s trajectory from neuroscience and naval research into the ketogenic space, detailing how high-oxygen environments, hyperbaric oxygen exposure, and redox biology illuminate brain energetics and seizure mechanisms. The conversation moves from foundational ketosis biology—how fasting, carbohydrate restriction, and beta-hydroxybutyrate shift brain fuel and gene regulation—to practical optimization: tracking ketones, proteins, and calories for athletes, the role of ketone esters versus ketone salts, and the need to balance electrolytes to prevent dehydration and dizziness during the transition to ketosis. They emphasize that nutritional ketosis is a metabolic therapy with pleiotropic effects, including neuroprotective signaling and anti-inflammatory potential, rather than a simple weight-loss protocol, and they stress individualized approaches guided by biomarkers and blood work.
The discussion then broadens to exogenous ketones as a bridge and tool, addressing pharmacokinetics, enantiomers, and the tradeoffs of different formulations. They compare monoesters, diesters, and salts, explain the D- versus L- beta-hydroxybutyrate dynamics, and reveal how mixing ketones with MCTs or other compounds can modulate absorption, insulin response, and brain energy delivery. Dom candidly shares experimental cautions about liver load, energy toxicity, and the importance of dosing strategies that avoid insulin spikes while maintaining a stable 1–2 millimolar ketone range for cognitive and physical work. The pair also dives into applications for cancer and brain disorders, outlining a framework for glioblastoma and the glucose-ketone index, and they discuss how metabolic therapy could complement standard-of-care options while acknowledging the current absence of definitive randomized trials for many cancers and neurodegenerative diseases. They close with candid reflections on ongoing clinical research, regulatory hurdles, and the hope that metabolic approaches—together with targeted drugs and immune therapies—could meaningfully extend survival and improve quality of life in difficult conditions like GBM and Alzheimer’s disease.